This article was originally published in The Gray Sheet
Oncto Trac lung cancer imaging product will be distributed in North America by DuPont Radiopharmaceuticals under an agreement announced Oct. 6. NeoRx will receive $2 mil. from DuPont Merck upon signing of the contract and an additional $4.5 mil. upon FDA approval of the small-cell lung cancer imaging kit, as well as product royalties. DuPont Merck will receive 269,000 shares of NeoRx common stock. The imaging kit, manufactured by Boehringer Ingelheim's wholly owned subsidiary Dr. Karl Thamae GmbH, is currently under review for final approval by FDA's Center for Biologics Evaluation and Research
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.